Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Allogene Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Of which not filed for Q2 2021 | Q2 2021 | Change |
|---|---|---|---|---|
| Holders | 169 | 1 | 182 | +14 |
| Shares | 88.4M | 7.00K | 86.3M | −2.03M (−2.3%) |
| Value | $3.12B | $247.0K | $2.25B | −$867.8M (−27.8%) |
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (41)
Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
Sold out (27)
Institutions that held Allogene Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
Not filed for Q2 2021 yet (1)
Institutions that held Allogene Therapeutics, Inc. at the end of Q1 2021 and haven't filed a 13F for Q2 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Amundi Asset Management US, Inc. | 7,000 | $247.0K |